AU9112201A - Pulmonary delivery in treating disorders of the central nervous system - Google Patents

Pulmonary delivery in treating disorders of the central nervous system

Info

Publication number
AU9112201A
AU9112201A AU9112201A AU9112201A AU9112201A AU 9112201 A AU9112201 A AU 9112201A AU 9112201 A AU9112201 A AU 9112201A AU 9112201 A AU9112201 A AU 9112201A AU 9112201 A AU9112201 A AU 9112201A
Authority
AU
Australia
Prior art keywords
nervous system
central nervous
pulmonary delivery
treating disorders
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU9112201A
Other languages
English (en)
Inventor
Raymond T Bartus
Dwaine R Emerich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Inhalation Research Inc
Original Assignee
Advanced Inhalation Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/665,252 external-priority patent/US6514482B1/en
Application filed by Advanced Inhalation Research Inc filed Critical Advanced Inhalation Research Inc
Publication of AU9112201A publication Critical patent/AU9112201A/xx
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU9112201A 2000-09-19 2001-09-19 Pulmonary delivery in treating disorders of the central nervous system Pending AU9112201A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/665,252 US6514482B1 (en) 2000-09-19 2000-09-19 Pulmonary delivery in treating disorders of the central nervous system
US09/877,734 US6613308B2 (en) 2000-09-19 2001-06-08 Pulmonary delivery in treating disorders of the central nervous system
PCT/US2001/029311 WO2002024158A2 (en) 2000-09-19 2001-09-19 Pulmonary delivery in treating disorders of the central nervous system

Publications (1)

Publication Number Publication Date
AU9112201A true AU9112201A (en) 2002-04-02

Family

ID=27099159

Family Applications (2)

Application Number Title Priority Date Filing Date
AU9112201A Pending AU9112201A (en) 2000-09-19 2001-09-19 Pulmonary delivery in treating disorders of the central nervous system
AU2001291122A Expired AU2001291122B2 (en) 2000-09-19 2001-09-19 Pulmonary delivery in treating disorders of the central nervous system

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001291122A Expired AU2001291122B2 (en) 2000-09-19 2001-09-19 Pulmonary delivery in treating disorders of the central nervous system

Country Status (10)

Country Link
US (7) US6613308B2 (enExample)
EP (2) EP3061453A1 (enExample)
JP (2) JP5421510B2 (enExample)
AU (2) AU9112201A (enExample)
CA (1) CA2421974C (enExample)
CY (1) CY1118851T1 (enExample)
DK (1) DK1318785T3 (enExample)
ES (1) ES2621549T3 (enExample)
PT (1) PT1318785T (enExample)
WO (1) WO2002024158A2 (enExample)

Families Citing this family (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020052310A1 (en) * 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US7779020B2 (en) * 2002-03-01 2010-08-17 International Business Machines Corporation Small-footprint applicative query interpreter method, system and program product
EP1105096B1 (en) 1998-08-19 2003-10-29 Skyepharma Canada Inc. Injectable aqueous dispersions of propofol
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
FR2812545B1 (fr) * 2000-08-03 2003-03-28 Air Liquide Sante Int Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6759029B2 (en) * 2001-05-24 2004-07-06 Alexza Molecular Delivery Corporation Delivery of rizatriptan and zolmitriptan through an inhalation route
ES2316571T3 (es) 2001-05-24 2009-04-16 Alexza Pharmaceuticals, Inc. Administracion de alprazolam, estazolam, midazolam o triazolam a traves de una via inhalatoria.
WO2002094238A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of anti-migraine compounds through an inhalation route
EP1392262A1 (en) * 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
DE60227660D1 (de) * 2001-05-24 2008-08-28 Alexza Pharmaceuticals Inc Freisetzung von antiemetika auf dem inhalationsweg
DE60231611D1 (de) * 2001-05-24 2009-04-30 Alexza Pharmaceuticals Inc Verabreichung von opioiden durch inhalation
AU2002259241B2 (en) * 2001-05-24 2008-09-04 Alexza Pharmaceuticals, Inc. Delivery of sedative-hypnotics through an inhalation route
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
WO2002094232A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of antidepressants through an inhalation route
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
EP1392260A2 (en) * 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of benzodiazepines through an inhalation route
US20080038363A1 (en) * 2001-05-24 2008-02-14 Zaffaroni Alejandro C Aerosol delivery system and uses thereof
DE60230502D1 (de) * 2001-05-24 2009-02-05 Alexza Pharmaceuticals Inc Verabreichung von antimigränemitteln durch inhalation
DE60230609D1 (de) * 2001-05-24 2009-02-12 Alexza Pharmaceuticals Inc Verabreichung von nichtsteroidalen entzündungshemmenden wirkstoffen durch inhalation
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
WO2002094237A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of beta-blockers through an inhalation route
DE10137633A1 (de) * 2001-08-03 2003-02-20 Boehringer Ingelheim Pharma Pramipexol zur Behandlung von ADHD
WO2003041693A1 (en) * 2001-11-09 2003-05-22 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
EP1446102A1 (en) 2001-11-21 2004-08-18 Alexza Molecular Delivery Corporation Delivery of caffeine through an inhalation route
ES2364636T3 (es) 2001-12-19 2011-09-08 Novartis Ag Administración pulmonar de aminoglucósidos.
SI1494732T1 (sl) 2002-03-20 2008-08-31 Mannking Corp Inhalacijski aparat
AU2003218308B2 (en) * 2002-03-20 2006-07-20 Advanced Inhalation Research, Inc. hGH (human growth hormone) formulations for pulmonary administration
EP2630954B1 (en) * 2002-03-20 2016-10-05 Civitas Therapeutics, Inc. Pulmonary delivery for levodopa
CA2483340A1 (en) * 2002-04-24 2003-11-06 Research Development Foundation Synergistic effects of nuclear transcription factor nf-.kappa.b inhibitors and anti-neoplastic agents
EP1503744A1 (en) 2002-05-13 2005-02-09 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
US20060193788A1 (en) * 2002-11-26 2006-08-31 Hale Ron L Acute treatment of headache with phenothiazine antipsychotics
JP2005535626A (ja) * 2002-06-24 2005-11-24 リサーチ　ディベロップメント　ファンデーション クルクミンによるヒト多発性骨髄腫の治療
US7947742B2 (en) * 2002-06-28 2011-05-24 Civitas Therapeutics, Inc. Inhalable epinephrine
CA2490308A1 (en) * 2002-07-12 2004-01-22 University Of Rochester Use of amino acids for treatment of various conditions
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
CA2507158A1 (en) * 2002-11-26 2004-06-10 Alexza Molecular Delivery Corporation Treatment of headache with antipsychotics delivered by inhalation
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
CA2507159A1 (en) * 2002-11-26 2004-06-10 Alexza Molecular Delivery Corporation Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
JP2006516963A (ja) * 2003-02-04 2006-07-13 クリサリス テクノロジーズ インコーポレイテッド エアロゾル製剤及びブスピロン、ブプレノルフィン、トリアゾラム、シクロベンザプリン及びゾルピデムのエアロゾル送出
JP2006522634A (ja) 2003-04-14 2006-10-05 ベクトゥラ・リミテッド 投与効率を向上させるデバイス及び製薬組成
JP2007516149A (ja) 2003-05-21 2007-06-21 アレックザ ファーマシューティカルズ， インコーポレイテッド 基板温度の均一性を制御する方法、および、内蔵式加熱ユニットおよびそれを使用する薬剤供給ユニット
ES2872350T3 (es) * 2003-06-13 2021-11-02 Civitas Therapeutics Inc Polvos farmacéuticos de dosis baja para inhalación
AU2004320907A1 (en) 2003-08-26 2006-04-13 Research Development Foundation Osteoclastogenesis inhibitors and uses thereof
WO2005020958A2 (en) * 2003-08-26 2005-03-10 Research Development Foundation Aerosol delivery of curcumin
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
EP1765288B1 (en) 2004-06-18 2012-11-07 Novartis AG Tobramycin formualtions for treatment of endobronchial infections
EP1781360A1 (en) 2004-08-12 2007-05-09 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
KR101273120B1 (ko) 2004-08-20 2013-06-13 맨카인드 코포레이션 다이케토피페라진 합성의 촉매 작용
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
AU2005290238A1 (en) 2004-09-18 2006-04-06 Department Of Veterans Affairs Therapeutic agents trageting the NCCa-ATP channel and methods of use thereof
WO2006034048A2 (en) 2004-09-18 2006-03-30 University Of Maryland, Baltimore Therapeutic agents targeting the ncca-atp channel and methods of use thereof
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20060134009A1 (en) * 2004-12-16 2006-06-22 Daniel Deaver Low dose corticosteroid powders for inhalation
US8466133B2 (en) 2005-04-22 2013-06-18 University Of Geneva Polylactides compositions and uses thereof
KR101486829B1 (ko) 2005-09-14 2015-01-29 맨카인드 코포레이션 결정질 미립자 표면에 대한 활성제의 친화력의 증가를 기반으로 하는 약물 제제의 방법
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
CA2674949A1 (en) 2007-01-12 2008-07-24 J. Marc Simard Targeting ncca-atp channel for organ protection following ischemic episode
US20080275030A1 (en) * 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
CA2677264C (en) 2007-02-02 2021-11-30 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US20100092469A1 (en) 2007-02-09 2010-04-15 Simard J Marc Antagonists of a non-selective cation channel in neural cells
DK2425820T3 (en) 2007-02-11 2015-07-13 Map Pharmaceuticals Inc A method for the therapeutic administration of DHE in order to enable quick relief of migraine, while minimizing the adverse event profile
EP2121088B1 (en) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
EP2167107B1 (en) 2007-06-22 2016-12-14 University of Maryland, Baltimore Inhibitors of ncca-atp channels for therapy
JP2010533181A (ja) * 2007-07-13 2010-10-21 アボツト・バイオテクノロジー・リミテツド ＴＮＦα阻害剤の肺投与のための方法及び組成物
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
GB2454480A (en) * 2007-11-07 2009-05-13 Vectura Group Plc Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
TWI677355B (zh) 2008-06-13 2019-11-21 美商曼凱公司 用於藥物傳輸之乾粉吸入器及系統
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
EP2328601B1 (en) * 2008-08-15 2020-01-22 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration
EP2340254B8 (en) * 2008-09-15 2014-05-21 Biovista, Inc. Compositions and methods for treating epilepsy
EP2326318A4 (en) 2008-09-16 2012-05-23 Univ Maryland SUR1 HEMMER FOR THERAPEUTIC PURPOSES
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
WO2010074753A1 (en) 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2676695A3 (en) 2009-03-11 2017-03-01 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
RU2577698C2 (ru) 2009-03-26 2016-03-20 Пулмэтрикс, Инк. Сухие порошкообразные составы и способы лечения легочных заболеваний
ES2702049T3 (es) 2009-04-24 2019-02-27 Univ Vanderbilt Inducción anti-TGF-beta de crecimiento óseo
MY186975A (en) 2009-06-12 2021-08-26 Mannkind Corp Diketopiperazine microparticles with defined specific surface areas
WO2011011781A1 (en) 2009-07-24 2011-01-27 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
MX2012001660A (es) * 2009-08-06 2012-03-26 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para adminstracion oral.
US9016147B2 (en) 2009-11-03 2015-04-28 Mannkind Corporation Apparatus and method for simulating inhalation efforts
CA2790213A1 (en) 2010-02-17 2011-08-25 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
MX359281B (es) 2010-06-21 2018-09-21 Mannkind Corp Sistema y metodos para suministrar un farmaco en polvo seco.
ES2919136T3 (es) 2010-08-11 2022-07-22 Ironwood Pharmaceuticals Inc Formulaciones estables de linaclotida
EP3192880B1 (en) 2010-08-18 2019-10-09 Fred Hutchinson Cancer Research Center Nucleic acid agents for use in treating facioscapulohumeral dystrophy (fshd)
US20130164338A1 (en) 2010-08-30 2013-06-27 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
RU2640921C2 (ru) 2010-09-29 2018-01-12 Пулмэтрикс, Инк. Катионы одновалентных металлов сухих порошков для ингаляций
US8925726B2 (en) 2011-04-01 2015-01-06 Mannkind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
EP2734634B1 (en) 2011-07-22 2019-08-21 The University of Chicago Igf-1 for use in the treatment of migraine
PL2776055T3 (pl) 2011-08-17 2017-06-30 Ironwood Pharmaceuticals, Inc. Sposoby leczenia zaburzeń żołądkowo-jelitowych
US9655905B2 (en) 2011-09-14 2017-05-23 King Abdullah University Of Science And Technology Treatment of sickle cell disease
EP2758519B1 (en) 2011-09-21 2017-03-29 King Abdullah University Of Science And Technology Didemnin biosynthetic gene cluster in tistrella mobilis
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
CA2852536A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
RS59734B1 (sr) 2012-01-23 2020-02-28 Sage Therapeutics Inc Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil etar beta-ciklodekstrina
AU2013221448B2 (en) 2012-02-16 2017-02-23 The University Of Toledo Xenoantigen-displaying anti-cancer vaccines and method of making
WO2013130422A1 (en) 2012-02-27 2013-09-06 Biovista, Inc. Compositions and methods for treating mitochondrial diseases
CA2865972C (en) 2012-02-29 2022-01-04 Pulmatrix, Inc. Inhalable dry powders
AR092821A1 (es) 2012-04-20 2015-05-06 Sucampo Ag Conjugado de derivado de acido graso-polimero
BR112014027834A2 (pt) 2012-05-23 2017-08-08 Univ Ohio State composições de nanopartícula lipídica para entrega de oligonucleotídeos antissenso
CA2878457C (en) 2012-07-12 2021-01-19 Mannkind Corporation Dry powder drug delivery systems and methods
WO2014028398A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
EP2887944B1 (en) 2012-08-21 2021-10-06 Sage Therapeutics, Inc. Allopregnanolone for treating refractory status epilepticus
KR102237007B1 (ko) * 2012-10-22 2021-04-06 키비타스 테라퓨틱스, 인코포레이티드. 레보도파 혈장 농도의 환자간 변산도의 감소
MX390106B (es) 2012-10-22 2025-03-20 Merz Pharmaceuticals Llc Formulaciones de levodopa para el alivio rapido de la enfermedad de parkinson
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
BR112015010601B1 (pt) * 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
US8545878B1 (en) * 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use
EP2925327B1 (en) 2012-11-30 2024-01-10 The Regents of The University of California Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression
US9757395B2 (en) * 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
FR3000392B1 (fr) * 2012-12-27 2015-03-27 Virbac Nouvelles compositions pharmaceutiques veterinaires et leur procede de preparation
US10208012B2 (en) 2013-03-13 2019-02-19 Board Of Regents, The University Of Texas System Compounds for treating inflammatory and hyperproliferative diseases
EP2970149B1 (en) 2013-03-15 2019-08-21 MannKind Corporation Microcrystalline diketopiperazine compositions and methods
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
CN105263551A (zh) * 2013-03-26 2016-01-20 奥普蒂诺斯公司 鼻腔给药
MX2015013845A (es) 2013-04-01 2016-05-09 Pulmatrix Inc Polvos secos de tiotropio.
JP2016518388A (ja) 2013-04-30 2016-06-23 オティトピック インク． 乾燥粉末配合および使用方法
EP3021834A1 (en) 2013-07-18 2016-05-25 MannKind Corporation Heat-stable dry powder pharmaceutical compositions and methods
CN105517607A (zh) 2013-08-05 2016-04-20 曼金德公司 吹入设备和方法
US10328127B2 (en) 2013-12-02 2019-06-25 Baylor College Of Medicine Methods for stimulation of appetite and increase in weight by administration of asprosin
CA2977083A1 (en) 2014-02-20 2015-08-27 Kambiz Yadidi Dry powder formulations for inhalation
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
WO2015157500A1 (en) 2014-04-09 2015-10-15 Research Development Foundation Class iia hdac inhibitors for the treatment of infection
SG11201608608PA (en) * 2014-04-21 2016-11-29 Civitas Therapeutics Inc Rapid relief of motor fluctuations in parkinson's disease
US10278986B2 (en) 2014-08-14 2019-05-07 The Regents Of The University Of Colorado, A Body Corporate Antibody-siRNA conjugates and uses therefor
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
CA2965759C (en) 2014-10-31 2023-12-12 Glaxosmithkline Intellectual Property Development Limited Powdered polypeptides with decreased disulfide impurities comprising divalent cationic materials
US10302644B2 (en) 2014-11-04 2019-05-28 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
US11285190B2 (en) 2015-04-20 2022-03-29 The Board Of Regents Of The University Of Texas System CLEC11a is a bone growth agent
AU2016257729A1 (en) * 2015-05-01 2017-11-09 Civitas Therapeutics, Inc. Zolmitriptan powders for pulmonary delivery
WO2016205615A1 (en) 2015-06-17 2016-12-22 The Johns Hopkins University Tdp-43 in degenerative disease
US10034857B2 (en) 2015-07-02 2018-07-31 Civitas Therapeutics, Inc. Triptan powders for pulmonary delivery
US10695322B2 (en) 2016-01-29 2020-06-30 The Johns Hopkins University Inhibitors of bacterial growth
WO2017143112A2 (en) 2016-02-17 2017-08-24 The Johns Hopkins University An oxazolidinone for treatment of infections with mycobacterium tuberculosis
WO2017147370A1 (en) 2016-02-24 2017-08-31 The Johns Hopkins University Novel antiviral proteins and their uses in therapeutic methods
US10888549B2 (en) 2016-03-07 2021-01-12 The Johns Hopkins University Pharmaceutical agents targeting cancer stem cells
AU2017229656B2 (en) 2016-03-08 2022-09-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MX2018010850A (es) 2016-03-10 2019-05-15 Univ Johns Hopkins Métodos para producir proteínas de fusión de toxina diftérica monoméricas y libres de agregados y usos terapéuticos.
US11203626B2 (en) 2016-03-10 2021-12-21 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
KR102889062B1 (ko) 2016-03-17 2025-11-21 더 존스 홉킨스 유니버시티 Paris의 파네실화에 의해 파킨슨병을 예방 또는 치료하기 위한 방법
WO2017173055A1 (en) 2016-03-30 2017-10-05 The Johns Hopkins University Olfr90 specificity and methods of detection
US11016085B2 (en) 2016-04-25 2021-05-25 The Johns Hopkins University ZNT8 assays for drug development and pharmaceutical compositions
EP3463378A4 (en) 2016-06-03 2020-01-08 Otitopic Inc. DRY POWDER FORMULAS FOR INHALATION
US11149275B2 (en) 2016-10-10 2021-10-19 The Johns Hopkins University Device and method to treat esophageal disorders
LT3551189T (lt) 2016-12-09 2024-02-12 Alexza Pharmaceuticals, Inc. Alprazolamas, skirtas vartoti gydant epilepsiją
US10434089B2 (en) 2017-01-25 2019-10-08 The Johns Hopkins University Avibactam and carbapenems antibacterial agents
WO2018170172A1 (en) 2017-03-14 2018-09-20 Baylor College Of Medicine Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal
US11892457B2 (en) 2017-07-12 2024-02-06 The Johns Hopkins University Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
KR102507987B1 (ko) 2017-09-22 2023-03-21 벡추라 인코포레이티드 스테아르산마그네슘을 갖는 건조 분말 조성물
US20200330541A1 (en) 2017-11-16 2020-10-22 University Of Maine System Board Of Trustees Compositions and methods for modulating endothelial cell migration and angiogenesis
WO2019118527A1 (en) 2017-12-14 2019-06-20 The Johns Hopkins University Novel anti-fungal inhibitors
US12214118B2 (en) 2018-02-02 2025-02-04 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device
WO2019173478A2 (en) 2018-03-06 2019-09-12 The Johns Hopkins University Methods of treating or preventing cancer with an agent that depletes tregs and a checkpoint inhibitor
WO2020028222A1 (en) 2018-07-29 2020-02-06 Musc Foundation For Research Development Compounds for the treatment of neurological or mitochondrial diseases
WO2020033130A1 (en) 2018-08-06 2020-02-13 The Johns Hopkins University Treatment of irritable bowel syndrome with molybdenum
US12103968B2 (en) 2018-08-16 2024-10-01 The Johns Hopkins University Antibodies to human ZnT8
WO2020163766A1 (en) 2019-02-07 2020-08-13 Baylor College Of Medicine Periosteal skeletal stem cells in bone repair
US11717506B2 (en) 2019-05-07 2023-08-08 The Johns Hopkins University Neuroprotective compounds for amyotrophic lateral sclerosis
US12366570B2 (en) 2019-10-01 2025-07-22 The Johns Hopkins University Cell-based ZNT8 assay
EP4081227A4 (en) 2019-12-26 2023-11-29 Figene, LLC Suppression of interleukin-17 production and inhibition of th17 cell generation by fibroblasts and products thereof
EP4081222A4 (en) 2019-12-26 2023-11-01 Figene, LLC PREVENTION AND TREATMENT OF KIDNEY FAILURE BY ADMINISTRATION OF FIBROBLASTS AND PRODUCTS THEREOF
IL296166A (en) 2020-03-04 2022-11-01 Pleopharma L L C Methods and preparations for treating cannabis use disorder and facilitating cannabinoid withdrawal
US20230383359A1 (en) 2020-10-23 2023-11-30 Mirati Therapeutics, Inc. Methods for treatment of lung cancers
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
JPS6122019A (ja) 1984-07-06 1986-01-30 Tomio Konno 吸入細胞活性薬品とその使用方法
GB8501015D0 (en) 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
AU587472B2 (en) 1985-05-22 1989-08-17 Liposome Technology, Inc. Liposome inhalation method and system
EP0259383B1 (de) * 1986-03-10 1991-01-23 Kurt Dr. Burghart Pharmazeutikum sowie verfahren zu seiner herstellung
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US6048857A (en) 1989-10-17 2000-04-11 Ellinwood, Jr.; Everett H. Dosing method of administering medicaments via inhalation administration
US5118494A (en) 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
CA2081474A1 (en) 1990-05-08 1991-11-09 Manzer Durrani Direct spray-dried drug/lipid powder composition
US5166202A (en) 1990-09-19 1992-11-24 Trustees Of The University Of Pennsylvania Method for the treatment of panic disorder
GB9101592D0 (en) 1991-01-24 1991-03-06 Glaxo Group Ltd Compositions
ATE179605T1 (de) * 1991-02-09 1999-05-15 B S D Bio Science Dev Snc Di O Antireaktive antiasthmatische wirkung von acetylsalicylsäure durch inhalation
DE69232003T2 (de) 1991-09-18 2002-04-25 Glaxo Group Ltd., Greenford Benzanilidderivate als 5-HT1D-Antagonisten
US5457100A (en) 1991-12-02 1995-10-10 Daniel; David G. Method for treatment of recurrent paroxysmal neuropsychiatric
US5756071A (en) 1992-06-03 1998-05-26 Arrowdean Limited Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier
US5284133A (en) 1992-07-23 1994-02-08 Armstrong Pharmaceuticals, Inc. Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means
AU5171293A (en) 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
KR100419037B1 (ko) 1994-03-07 2004-06-12 넥타르 테라퓨틱스 폐를통한인슐린의전달방법및그조성물
AU696387B2 (en) * 1994-05-18 1998-09-10 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
CA2152684A1 (en) 1994-07-01 1996-01-02 Richard Anthony Henry Aerosol delivery of midazolam
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
US5875776A (en) 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6503480B1 (en) * 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6103270A (en) 1996-06-07 2000-08-15 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
ZA9711732B (en) * 1996-12-31 1998-12-28 Quadrant Holdings Cambridge Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
EP0954282B1 (en) 1997-01-16 2005-01-19 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5958902A (en) 1997-04-16 1999-09-28 Wisconsin Alumni Research Foundation Method and composition for treating sleep apnea
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
IL146659A0 (en) 1999-05-27 2002-07-25 Acusphere Inc Porous drug matrices and method of manufacture thereof
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
WO2002094243A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route
US7090830B2 (en) * 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits

Also Published As

Publication number Publication date
DK1318785T3 (en) 2017-04-03
US6613308B2 (en) 2003-09-02
ES2621549T3 (es) 2017-07-04
US20030235537A1 (en) 2003-12-25
US20140193501A1 (en) 2014-07-10
EP1318785B1 (en) 2016-12-21
JP2004509141A (ja) 2004-03-25
WO2002024158A2 (en) 2002-03-28
JP2012180378A (ja) 2012-09-20
AU2001291122B2 (en) 2005-03-10
US6979437B2 (en) 2005-12-27
US20120087952A1 (en) 2012-04-12
JP5421510B2 (ja) 2014-02-19
WO2002024158A8 (en) 2003-02-20
EP3061453A1 (en) 2016-08-31
EP1318785A2 (en) 2003-06-18
CY1118851T1 (el) 2018-01-10
WO2002024158A3 (en) 2002-09-19
US20040228923A1 (en) 2004-11-18
PT1318785T (pt) 2017-04-19
US20040265242A1 (en) 2004-12-30
CA2421974A1 (en) 2002-03-28
US20020058009A1 (en) 2002-05-16
CA2421974C (en) 2011-03-29
US20090162441A1 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
AU9112201A (en) Pulmonary delivery in treating disorders of the central nervous system
PT2266594E (pt) Vegf para utilização no tratamento de distúrbios do sistema nervoso central
GB0007193D0 (en) Treatment of movrmrnt disorders
PL373626A1 (en) Treatment for central nervous system disorders
IL151946A0 (en) 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
HUP0401023A3 (en) Use of flibanserin in the treatment of sexual disorders
HUP0203529A3 (en) Treating sleep disorders using desloratadine
ZA200204493B (en) Pharmaceutical combinations and their use in treating gastrointestinal disorders.
AU2002361811A8 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
GB0015225D0 (en) Novel substituted nitrocatechols their use in the tratment of some central and peripheral nervous system disorders
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
IL153236A0 (en) The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
PL363219A1 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders
IL156340A0 (en) 3-indoline derivatives useful in the treatment of psychiatric and neurologic disorders
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
IL150289A0 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine
GB0015228D0 (en) Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders
AU2002215047A1 (en) Isoquinoline derivatives useful in the treatment of cns disorders
GB0128674D0 (en) Treatment of sleep disorders and the like
IL150290A0 (en) The use of mirtazapine for the treatment of sleep disorders
HUP0301553A3 (en) Pharmaceutical compositions and their use for treating neurological disorders
MXPA03004190A (es) Tratamiento de trastornos de ansiedad.
GB0105694D0 (en) Online transaction ledger
IL140117A0 (en) Use of optically pure (-) norcisapride in the treatment of apnea, bulimia and other disorders
ZA200108289B (en) Use of osanetant in the production of medicaments used to treat mood disorders.